Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP47 | Q96K76 | 6/20 | 0.62 |
| ▸ | USP7 | Q93009 | 9/20 | 0.60 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.60 |
| ▸ | PDE7A | Q13946 | 6/20 | 0.48 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | USP10 | Q14694 | 1/20 | 0.44 |
| ▸ | DTYMK | P23919 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1455298 | 0.89 | USP47 (0.65) | USP47USP7PADI4MAPTUSP10 | |
| SCHEMBL1455594 | 0.82 | USP7 (0.55) | USP47USP7PADI4PDE7AMEN1 | |
| SCHEMBL27889362 | 0.79 | USP47 (0.57) | USP47USP7PADI4USP10P2RY14 | |
| SCHEMBL1455158 | 0.77 | USP7 (0.49) | USP47USP7PADI4MEN1MAPT | |
| SCHEMBL2680315 | 0.76 | USP7 (0.79) | USP47USP7PADI4PDE7AMEN1 | |
| SCHEMBL2681880 | 0.75 | USP47 (0.85) | USP47USP7PADI4MEN1MAPT | |
| SCHEMBL2681089 | 0.75 | USP7 (0.77) | USP47USP7PADI4PDE7AMAPT | |
| SCHEMBL2681075 | 0.75 | USP7 (1.00) | USP47USP7PADI4PDE7APDE7B | |
| SCHEMBL2681219 | 0.75 | USP7 (0.79) | USP47USP7PADI4 | |
| SCHEMBL2680882 | 0.73 | USP7 (0.80) | USP47USP7PADI4PDE7AUSP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101384591-A | Antiviral compounds | ABBOTT LAB (US) | 2009-03-11 | — | — | CN | disclosed |
| EP-1979348-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007076034-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | USP47 1620/4885USP7 1912/4885PADI4 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.